GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (CHIX:GMABc) » Definitions » Beneish M-Score

Genmab AS (CHIX:GMABC) Beneish M-Score : 6.98 (As of Mar. 14, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Genmab AS Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 6.98 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Genmab AS's Beneish M-Score or its related term are showing as below:

CHIX:GMABc' s Beneish M-Score Range Over the Past 10 Years
Min: -3.08   Med: -1.75   Max: 6.98
Current: 6.98

During the past 13 years, the highest Beneish M-Score of Genmab AS was 6.98. The lowest was -3.08. And the median was -1.75.


Genmab AS Beneish M-Score Historical Data

The historical data trend for Genmab AS's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Beneish M-Score Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.21 -2.64 -1.88 -3.08 6.98

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.08 -2.49 5.31 6.12 6.98

Competitive Comparison of Genmab AS's Beneish M-Score

For the Biotechnology subindustry, Genmab AS's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Genmab AS's Beneish M-Score falls into.



Genmab AS Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Genmab AS for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0351+0.528 * 1.0336+0.404 * 24.3138+0.892 * 1.3067+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8971+4.679 * -0.028137-0.327 * 1.5204
=6.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was kr6,691 Mil.
Revenue was 6441 + 5540 + 5402 + 4143 = kr21,526 Mil.
Gross Profit was 6104 + 5267 + 5212 + 3958 = kr20,541 Mil.
Total Current Assets was kr27,854 Mil.
Total Assets was kr45,811 Mil.
Property, Plant and Equipment(Net PPE) was kr1,891 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0 Mil.
Selling, General, & Admin. Expense(SGA) was kr3,865 Mil.
Total Current Liabilities was kr5,308 Mil.
Long-Term Debt & Capital Lease Obligation was kr937 Mil.
Net Income was 3845 + 1266 + 1408 + 1325 = kr7,844 Mil.
Non Operating Income was 1241 + -544 + 38 + 627 = kr1,362 Mil.
Cash Flow from Operations was 2712 + 2033 + 1513 + 1513 = kr7,771 Mil.
Total Receivables was kr4,947 Mil.
Revenue was 4759 + 4712 + 4169 + 2834 = kr16,474 Mil.
Gross Profit was 4633 + 4633 + 4148 + 2834 = kr16,248 Mil.
Total Current Assets was kr33,139 Mil.
Total Assets was kr35,289 Mil.
Property, Plant and Equipment(Net PPE) was kr1,641 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0 Mil.
Selling, General, & Admin. Expense(SGA) was kr3,297 Mil.
Total Current Liabilities was kr2,484 Mil.
Long-Term Debt & Capital Lease Obligation was kr680 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6691 / 21526) / (4947 / 16474)
=0.310833 / 0.300291
=1.0351

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(16248 / 16474) / (20541 / 21526)
=0.986281 / 0.954241
=1.0336

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (27854 + 1891) / 45811) / (1 - (33139 + 1641) / 35289)
=0.350702 / 0.014424
=24.3138

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=21526 / 16474
=1.3067

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1641)) / (0 / (0 + 1891))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3865 / 21526) / (3297 / 16474)
=0.17955 / 0.200134
=0.8971

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((937 + 5308) / 45811) / ((680 + 2484) / 35289)
=0.136321 / 0.08966
=1.5204

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(7844 - 1362 - 7771) / 45811
=-0.028137

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Genmab AS has a M-score of 6.98 signals that the company is likely to be a manipulator.


Genmab AS Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Genmab AS's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines